CAZZANIGA, GIOVANNI

CAZZANIGA, GIOVANNI  

DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)  

Mostra records
Risultati 1 - 20 di 287 (tempo di esecuzione: 0.008 secondi).
Titolo Tipologia Data di pubblicazione Autori File
Biallelic PI4KA Mutations Disrupt B-Cell Metabolism and Cause B-Cell Lymphopenia and Hypogammaglobulinemia 01 - Articolo su rivista 2025 Saettini, FrancescoGuerra, FabiolaMauri, MarioChinello, CliziaDenti, VannaFazio, GraziaMalighetti, FedericaPagani, LisaQuadri, ManuelRebellato, StefanoSavino, Angela MariaMagni, FulvioPaglia, GiuseppeCazzaniga, GianniPiazza, RoccoBiondi, Andrea +
Analysis of measurable residual disease by IG/TR gene rearrangements: quality assurance and updated EuroMRD guidelines 01 - Articolo su rivista 2024 Cazzaniga G. +
Clinical pilot study on microfluidic automation of IGH-VJ library preparation for next generation sequencing 01 - Articolo su rivista 2024 Rigamonti S.Cazzaniga G. +
Cytogenetically Balanced Reciprocal Translocation Could Hide Molecular Genomic Unbalances: Implications for Foetal Phenotype Correlation 01 - Articolo su rivista 2024 Villa N.Redaelli S.Farina S.Sala E.Crosti F.Cozzolino S.Verderio M.Roversi G.Bentivegna A.Cazzaniga G.Lavitrano M.Conconi D. +
Distinct pattern of genomic breakpoints in CML and BCR::ABL1-positive ALL: analysis of 971 patients 01 - Articolo su rivista 2024 Bardini M.Cazzaniga G. +
Diverse mechanisms of leukemogenesis associated with PAX5 germline mutation 01 - Articolo su rivista 2024 Bettini L. R.Fazio G.Saitta C.Piazza R.Palamini S.Buracchi C.Rebellato S.Biondi A.Cazzaniga G. +
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis 01 - Articolo su rivista 2024 Crespiatico I.Mastini C.D'Aliberti D.Mauri M.Mercado C. M.Fontana D.Spinelli S.Crippa V.Inzoli E.Manghisi B.Civettini I.Ramazzotti D.Sangiorgio V.Brambilla V.Aroldi A.Barone C.Orsenigo R.Serafini M.Mottadelli F.Cazzaniga G.Pagni F.Azzoni E.Gambacorti Passerini C.Elli E. M.Mologni L.Piazza R. +
Four Additional Doses of PEG-L-Asparaginase during the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study 01 - Articolo su rivista 2024 Valsecchi M. G.Rizzari C.Cazzaniga G.Biondi A. +
Idiopathic erythrocytosis: a germline disease? 01 - Articolo su rivista 2024 Elli, E. M.Mauri, M.D’Aliberti, D.Crespiatico, I.Fontana, D.Redaelli, S.Pelucchi, S.Spinelli, S.Manghisi, B.Cavalca, F.Aroldi, A.Ripamonti, A.Palamini, S.Mottadelli, F.Massimino, L.Ramazzotti, D.Cazzaniga, G.Piperno, A.Gambacorti-Passerini, C.Piazza, R. +
NG2 is a target gene of MLL-AF4 and underlies glucocorticoid resistance in MLL-r B-ALL by regulating NR3C1 expression 01 - Articolo su rivista 2024 Bardini M.Cazzaniga G. +
PAX5::AUTS2 childhood B-ALL: a relapse-prone genetic subtype with frequent central nervous system involvement and a poor outcome: ACUTE LYMPHOBLASTIC LEUKEMIA 01 - Articolo su rivista 2024 Fazio G.Cazzaniga G. +
Prenatal origin of NUTM1 gene rearrangement in infant B-cell precursor acute lymphoblastic leukaemia 01 - Articolo su rivista 2024 Bardini M.Fazio G.Sala S.Palamini S.Rebellato S.Rizzari C.Biondi A.Cazzaniga G. +
Synergistic drug interactions of the histone deacetylase inhibitor givinostat (ITF2357) in CRLF2-rearranged pediatric B-cell precursor acute lymphoblastic leukemia identified by high-throughput drug screening 01 - Articolo su rivista 2024 Oikonomou A.Valsecchi L.Savino A. M.Bardini M.Fazio G.Biondi A.Cazzaniga G.Palmi C. +
The gray area of RQ-PCR-based measurable residual disease: subdividing the “positive, below quantitative range” category 01 - Articolo su rivista 2024 Cazzaniga G. +
Antibody Deficiency in Patients with Biallelic KARS1 Mutations 01 - Articolo su rivista 2023 Saettini F.Guerra F.Fazio G.Ardissone A.Quadri M.Mauri M.Piazza R.Cazzaniga G.Biondi A. +
BEYOND THE TUMOUR: CHILDHOOD CANCER PREDISPOSING SYNDROMES [Guardare oltre il tumore: le cancer-predisposingsyndrome in età pediatrica] 01 - Articolo su rivista 2023 Bettini L. R.Lauriola R. S.Coliva T.Biondi A.Cazzaniga G. +
Clinical characteristics and outcomes of B-cell precursor ALL with MEF2D rearrangements: a retrospective study by the Ponte di Legno Childhood ALL Working Group 01 - Articolo su rivista 2023 Cazzaniga G. +
Correction to: Antibody Deficiency in Patients with Biallelic KARS1 Mutations (Journal of Clinical Immunology, (2023), 43, 8, (2115-2125), 10.1007/s10875-023-01584-7) 99 - Altro 2023 Saettini F.Guerra F.Fazio G.Ardissone A.Romano R.Quadri M.Gasperini S.Mauri M.Piazza R.Cazzaniga G.Biondi A. +
Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2) 99 - Altro 2023 Cazzaniga G. +
Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial 01 - Articolo su rivista 2023 Valsecchi M. G.Cazzaniga G.Biondi A. +